Señales en vivo de RETA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 sept 2023 @ 16:00):

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...

Stats
Volumen de hoy	1.91M
Volumen promedio	954 093
Capitalización de mercado	6.57B
EPS	$0 ( 2024-02-22 )
Próxima fecha de ganancias	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-66.29
ATR14	$1.830 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-26	Desai Antal Rohit	Sell	134	Class A common stock
2023-09-26	Desai Antal Rohit	Sell	993 929	Class B common stock
2023-09-26	Mcgaughy R Kent Jr	Sell	280	Class A common stock
2023-09-26	Mcgaughy R Kent Jr	Sell	278 309	Class B common stock
2023-09-26	Mcgaughy R Kent Jr	Sell	699	Stock Option (right to buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 4 695 639

Volumen Correlación

Largo: 0.09 (neutral)

Corto: -0.26 (neutral)

Signal:(84.692) Neutral

Reata Pharmaceuticals Inc Correlación

10 Correlaciones Más Positivas
CREX	0.957
MYRG	0.875
ALLR	0.869
MSSA	0.849
SGEN	0.847
NETE	0.835
PLYA	0.832
MHUA	0.831
USAP	0.83
SGTX	0.825

10 Correlaciones Más Negativas
RMGBU	-0.875
ENVI	-0.851
EJFA	-0.838
ONEM	-0.837
ESSA	-0.837
SVOK	-0.824
SAII	-0.819
FNCB	-0.818
BSBK	-0.816
PAIC	-0.814

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Reata Pharmaceuticals Inc Correlación - Moneda/Commodity

-0.12
( neutral )

0.63
( weak )

0.56
( weak )

0.12
( neutral )

-0.30
( neutral )

0.16
( neutral )

Reata Pharmaceuticals Inc Finanzas

Annual	2022
Ingresos:	$2.22M
Beneficio Bruto:	$2.22M (100.00 %)
EPS:	$-8.59

FY	2022
Ingresos:	$2.22M
Beneficio Bruto:	$2.22M (100.00 %)
EPS:	$-8.59

FY	2021
Ingresos:	$11.49M
Beneficio Bruto:	$11.49M (100.00 %)
EPS:	$-8.19

FY	2020
Ingresos:	$9.02M
Beneficio Bruto:	$9.02M (100.00 %)
EPS:	$-7.35

Financial Reports:

No articles found.

Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.